Healthcare
Services - Others
Indegene reported 1QFY27 performance in line with expectations, with revenue rising 2.5% QoQ and 26.5% YoY to USD113m. We expect INR revenue/EBIT/PAT to grow 26%/29%/35% YoY in FY27, along with mid-teen organic CC revenue growth and a gradual margin expansion, leading us to reiterate our Neutral rating with a target price of INR570.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
